Prevalence, Incidence and Patient Characteristics of Chronic Heart Failure (CHF) and the Predicted Subtypes HFrEF(<40%), HFpEF(≥40%) in Japan and United States

Study identification

• EU PAS number:
  EUPAS40997
• Study ID:
  45334
• Official title and acronym:
  Prevalence, Incidence and Patient Characteristics of Chronic Heart Failure (CHF) and the Predicted Subtypes HFrEF(<40%), HFpEF(≥40%) in Japan and United States
• DARWIN EU® study:
  No
• Study countries:
  Japan
• Study description:
  The primary objective of this study is to estimate the prevalence of Japan and US CHF patients using large population based claims and EMR databases. The secondary objectives are to estimate the incidence of CHF patients in Japan and USA, in addition, comparison of CHF patient characteristics and treatment pattern in the two countries will be made. Furthermore, as an exploratory objective, we will estimate the ratio of HFrEF/HFpEF using predictive modeling (Desai et al Circ Cardiovasc Qual Outcomes. 2018) for comparison with previously published ratio using Japanese heart failure registry data (Tsuchihashi-Makana et al, Circ J 2013)
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned: 28/01/2021

Actual: 09/03/2021

Study start date

Planned: 03/05/2021

Actual: 04/05/2021

Data analysis start date

Planned: 21/04/2022

Actual: 20/05/2021

Date of final study report

Planned: 22/12/2021

Actual: 10/01/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Nippon Boehringer Ingehleim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable